08/07/2026
Advancing critical care through continuous learning.
Glimpses from the ISCCM Surat Branch Monthly CME held last month on 19 June 2026 at Hilton Garden Inn, Surat.
The session, "Managing MDR Gram-Positive Infections in the ICU: Current Challenges & Emerging Options," was delivered by Dr. Pratik Savaj, Infectious Diseases Specialist.
Key Takeaways:
• Multiple therapeutic options are available for serious Gram-positive infections, including glycopeptides, oxazolidinones, lipopeptides, lipoglycopeptides, and newer agents.
• Antimicrobial selection should be individualized based on the site of infection, susceptibility profile, severity of illness, need for prolonged therapy, and patient-specific safety considerations.
• Levonadifloxacin is a newer anti-Gram-positive agent with potent activity against MRSA, including biofilm-associated infections, along with good tissue pe*******on, a favorable PK/PD profile, and both IV and oral formulations.
• It requires no dose adjustment in patients with renal impairment and has a lower risk of nephrotoxicity compared with glycopeptides.
• Unlike conventional fluoroquinolones, levonadifloxacin has demonstrated a favorable safety profile, with no clinically significant QT prolongation, no significant CNS toxicity or seizure signal, no reported tendinitis or tendon rupture, and minimal drug-drug interactions.
• Levonadifloxacin may be a valuable option for selected MRSA infections, particularly when prolonged therapy, oral step-down treatment, biofilm activity, renal dysfunction, or intolerance to conventional anti-MRSA agents limits therapeutic choices. However, antimicrobial selection should always be guided by source control, microbiological data, infection severity, and patient-specific factors.
Thank you to all the delegates who joined us for an engaging evening of learning and knowledge sharing.
Together, we continue to strengthen critical care practice through education.
